The emerging fields of suicide gene therapy and virotherapy.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Trends in Molecular Medicine

• Publication date

  2002-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1471-4914(02)02318-3PMID 11927291
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

  2001cited by this paper
• Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

  2001cited by this paper
• A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

  2000cited by this paper
• Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

  2000cited by this paper
• An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

  2000cited by this paper
• Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

  2000cited by this paper
• Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.

  2000cited by this paper
• Prodrug-activating systems in suicide gene therapy.

  2000cited by this paper
• Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

  2000cited by this paper
• A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo

  2000cited by this paper
• Replication-selective microbiological agents: fighting cancer with targeted germ warfare.

  2000cited by this paper
• Deletion of the Adenoviral E1b-19kD Gene Enhances Tumor Cell Killing of a Replicating Adenoviral Vector

  2000cited by this paper
• Regressions of Established Breast Carcinoma Xenografts by Carboxypeptidase G2 Suicide Gene Therapy and the Prodrug CMDA Are Due to a Bystander Effect

  2000cited by this paper
• Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein

  2000cited by this paper
• Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase.

  1999cited by this paper
• Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells.

  1999cited by this paper
• Patent property of suicide gene therapy involving prodrugs 1996 - 1999

  1999cited by this paper
• p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication

  1999cited by this paper
• Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae.

  1999cited by this paper
• Improving enzymes for cancer gene therapy

  1999cited by this paper
• The Design of Selectively‐activated Anti‐cancer Prodrugs for use in Antibody‐directed and Gene‐directed Enzyme‐Prodrug Therapies *

  1998cited by this paper
• ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

  1998cited by this paper
• A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy

  1998cited by this paper
• Gene-directed enzyme prodrug therapy.

  1998cited by this paper
• ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

  1997cited by this paper
• Gene therapy for cancer: what have we done and where are we going?

  1997cited by this paper
• A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy

  1997cited by this paper
• Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

  1997cited by this paper
• Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.

  1996cited by this paper
• An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

  1996cited by this paper
• Targeted gene delivery by tropism-modified adenoviral vectors

  1996cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

  1995cited by this paper
• Advances in cancer gene therapy.

  1995cited by this paper
• The properties of p53 proteins selected for the loss of suppression of transformation.

  1994cited by this paper
• Adenovirus E1A-p105(Rb) protein interactions play a direct role in the initiation but not the maintenance of the rodent cell transformed phenotype.

  1991cited by this paper
• Experimental therapy of human glioma by means of a genetically engineered virus mutant

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.

  1991cited by this paper
• The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations.

  1990cited by this paper
• Cellular targets for transformation by the adenovirus E1A proteins.

  1989cited by this paper
• Two regions of the adenovirus early region 1A proteins are required for transformation

  1988cited by this paper
• Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection.

  1987cited by this paper
• Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method.

  1985cited by this paper
• Adenovirus 2 lp+ locus codes for a 19 kd tumor antigen that plays an essential role in cell transformation

  1983cited by this paper

• Bacteria and viruses in gene therapy: An evidence-based review

  2024cites this paper
• Gene Therapy and Gene Editing for Cancer Therapeutics

  2021cites this paper
• ROLE OF BIOTECHNOLOGY IN PHARMACEUTICAL RESEARCH: A COMPREHENSIVE REVIEW

  2020cites this paper
• Designing Personalized and Innovative Novel Drug Therapies for Cancer Treatment

  2020cites this paper
• Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

  2020cites this paper
• The Use of Normal Stem Cells and Cancer Stem Cells for Potential Anti-Cancer Therapeutic Strategy

  2018cites this paper
• Conditional Toxin Splicing Using a Split Intein System.

  2017cites this paper
• Split Inteins

  2017cites this paper
• Dendrimer technologies for brain tumor.

  2016cites this paper
• Conditional protein splicing of α-sarcin in live cells.

  2014cites this paper
• Systemic tumor-specific gene delivery.

  2013cites this paper
• Experimental adenovirus gene therapy for cancer patients with advanced tumors : Translational medicine from basic research to the patient's bedside

  2013cites this paper
• Toxin-Based Cancer Gene Therapy: Under the Control of Oncofetal H19 Regulatory Sequences

  2013cites this paper
• Adenoviral gene therapy in hepatocellular carcinoma: a review

  2012cites this paper
• Retroviral replicating vectors in cancer.

  2012cites this paper
• Anti-leukemic activity of Newcastle disease virus strains AF2240 and V4-UPM in murine myelomonocytic leukemia in vivo.

  2012cites this paper
• Cellular Vehicles for Cancer Gene Therapy

  2012cites this paper
• Suicide genes in a novel vaccination strategy for hepatitis C.

  2012cites this paper
• Antitumor therapeutic effects of cytosine deaminase and interferon-β against endometrial cancer cells using genetically engineered stem cells in vitro.

  2011cites this paper
• Optimizing the Enzyme/Prodrug Axis of Suicide Gene Therapy Using Protein Engineering Strategies

  2011cites this paper
• Gene Transfer with Plasmid Biopharmaceuticals

  2011cites this paper
• [Ultrasound-mediated gene delivery].

  2011cites this paper
• An introduction to DNA technologies and their role in livestock production: a review.

  2010cites this paper
• Fundamentals of Molecular Biology and Gene Therapy

  2010cites this paper
• Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model.

  2009cites this paper
• Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment.

  2009cites this paper
• Prostate cancer targeting using replication-selective adenoviruses in combination with phytochemicals

  2009cites this paper
• Genetic control of wayward pluripotent stem cells and their progeny after transplantation.

  2009cites this paper
• Adenoviral gene therapy in gastric cancer: a review.

  2008cites this paper
• Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene

  2008cites this paper
• Alkylating agents and cancer therapy

  2007cites this paper
• A New Non-viral Conjugate as a Promising Carrier System for DNA Delivery

  2007cites this paper
• A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus

  2007cites this paper
• Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy

  2007cites this paper
• Models for Gene Therapy

  2007cites this paper
• Survivin and Granzyme B–induced apoptosis, a novel anticancer therapy

  2006cites this paper
• Gene therapy for gastric cancer: is it promising?

  2006cites this paper
• Studies on viral gene transfer and angiogenesis inhibition in experimental glioma models

  2006cites this paper
• Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.

  2006cites this paper
• Osteoclasts direct bystander killing of bone cancer.

  2006influential citation
• Connexin Over-Expression Differentially Suppresses Glioma Growth and Contributes to the Bystander Effect Following HSV-Thymidine Kinase Gene Therapy

  2006cites this paper
• Osteoclasts direct bystander killing of cancer cells in vitro.

  2006cites this paper
• Vector-mediated cancer gene therapy: An overview

  2005cites this paper
• Rodent models of brain metastasis in melanoma

  2005cites this paper
• [Glucuronyl paclitaxel (Taxol) derivatives as tumor activated prodrugs].

  2005cites this paper
• Expressing engineered thymidylate kinase variants in human cells to improve AZT phosphorylation and human immunodeficiency virus inhibition.

  2005cites this paper
• The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

  2005cites this paper
• Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?

  2005cites this paper
• Effect of hypoxia on Ad5 infection, transgene expression and replication

  2005cites this paper
• RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer.

  2005cites this paper
• Prodrogues glucuronylées du paclitaxel (Taxol®) activables au niveau des tumeurs

  2005cites this paper
• Proapoptotic Strategy in Cancer Gene Therapy

  2005cites this paper
• Anemia and gene therapy--a matter of control.

  2005cites this paper
• Molecular Engineering of Vector-Based Oncolytic and Imaging Approaches for Advanced Prostate Cancer

  2005cites this paper
• Viral vectors for cancer gene therapy: viral dissemination and tumor targeting.

  2005cites this paper
• Thérapie génique des déficits immunitaires sévères : preuve de principe d’efficacité et problèmes soulevés. Thérapie génique, déficits immunitaires, rétrovirus, lentivirus, génome

  2005cites this paper
• Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors

  2005cites this paper
• Vector-Mediated Cancer Gene Therapy

  2005cites this paper
• Fluorescent lipopolyamines in non-viral gene therapy.

  2005cites this paper
• Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects.

  2005cites this paper
• 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene

  2004cites this paper
• Current strategies in cancer gene therapy.

  2004cites this paper
• Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy

  2004cites this paper
• Vaccinia as a vector for gene delivery

  2004cites this paper
• Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

  2004cites this paper
• Genes for Cancer Therapy System to Enhance Delivery of P 450 Prodrug-Activation Use of Replication-Conditional Adenovirus as a Helper Updated

  2004cites this paper
• Drug delivery systems for brain tumor therapy.

  2004cites this paper
• Adenovirus endocytosis

  2004cites this paper
• An overview of current delivery systems in cancer gene therapy.

  2004cites this paper
• Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus

  2004cites this paper
• Highly specific transgene expression mediated by a complex adenovirus vector incorporating a prostate-specific amplification feedback loop

  2004cites this paper
• Induction of apoptosis in oral cancer cells: agents and mechanisms for potential therapy and prevention.

  2004cites this paper
• Characterization of CD20-Transduced T Lymphocytes as an Alternative Suicide Gene Therapy Approach for the Treatment of Graft-Versus-Host Disease

  2004cites this paper
• Cytogenetic detection of a trans-species bystander effect: induction of sister chromatid exchanges in murine 3T3 cells by ganciclovir metabolized in HSV thymidine kinase gene-transfected Chinese hamster ovary cells.

  2004cites this paper
• Genes in the service of therapeutic index: progress for virus-directed enzyme prodrug therapy.

  2004cites this paper
• Elongation factor 1 (EF1alpha) promoter in a lentiviral backbone improves expression of the CD20 suicide gene in primary T lymphocytes allowing efficient rituximab-mediated lysis.

  2004cites this paper
• Replicating adenoviruses targeting tumours with constitutive activation of the Wnt signalling pathway

  2004cites this paper
• Targeting RAS signalling pathways in cancer therapy

  2003cites this paper
• The feasibility of coating cationic liposomes with malaria circumsporozoite (CS) region II+ peptide for hepatocyte selective targeting

  2003cites this paper
• Adenovirus endocytosis

  2003cites this paper
• An overview on the development of newcastle disease virus as an anti-cancer therapy.

  2003cites this paper
• Methodes et trousses pour le diagnostic et le traitement de la leucemie lymphoide chronique de cellule b (b-cll)

  2003cites this paper
• Processing and characterisation of liposomes for use in gene delivery

  2003cites this paper
• Structure-activity relationship in cationic lipid mediated gene transfection.

  2003cites this paper
• Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases

  2003cites this paper
• Integrated, molecular engineering approaches to develop prostate cancer gene therapy.

  2003cites this paper
• Gene therapy: theoretical and bioethical concepts.

  2003cites this paper
• Transfection of MS‐36 melanoma cells with gef gene inhibits proliferation and induces modulation of the cell cycle

  2003cites this paper
• Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene.

  2003cites this paper
• Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes

  2002cites this paper
• The impact of genomic and proteomic technologies on the development of new cancer drugs.

  2002cites this paper
• An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell.

  2002cites this paper
• Deletion of the Adenoviral E1b-19kD Gene Enhances Tumor Cell Killing of a Replicating Adenoviral Vector

  2000cites this paper